Consensus Forte Biosciences, Inc.

Equities

FBRX

US34962G1094

Market Closed - Nasdaq Other stock markets 03:58:21 2024-06-04 pm EDT			5-day change	1st Jan Change
0.5984 ^USD	+3.00%		+3.19%	-27.18%

May. 30	Brookline Capital Initiates Forte Biosciences at Buy Rating With $4 Price Target	MT
May. 13	Forte Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Evolution of the average Target Price on Forte Biosciences, Inc.

Price target over the last 5 years

History of analyst recommendation changes

027.ooMAWpgFkzVV6jsicPLB4U_IHqUY3jRUBJ1Dz0uy_7c.7uw1Ivt8y19isEwUE6SigxqaZpJsikAhKd57on_Lz_ThsXRq_z2hfWaNAw~878ff20faa758b3c14012e43dee47576

Analyst Recommendations on Forte Biosciences, Inc.

Brookline Capital Initiates Forte Biosciences at Buy Rating With $4 Price Target	May. 30	MT
FORTE BIOSCIENCES : Chardan Capital Upgrades Forte Biosciences to Neutral From Sell Following Recent Selloff, Adjusts Price Target to $3.50 From $4	21-09-20	MT
FORTE BIOSCIENCES : Ladenburg Thalmann Downgrades Forte Biosciences to Neutral From Buy	21-09-07	MT
FORTE BIOSCIENCES : Brookline Capital Downgrades Forte Biosciences to Hold from Buy	21-09-07	MT
FORTE BIOSCIENCES : Chardan Downgrades Forte Biosciences to Sell From Buy, Adjusts Price Target to $4 From $105; Shares Slide 80% Premarket	21-09-03	MT
FORTE BIOSCIENCES : Ladenburg Thalmann Downgrades Forte Biosciences to Neutral from Buy	21-09-03	MT
FORTE BIOSCIENCES : B. Riley Downgrades Forte Biosciences to Neutral from Buy After Lead Program FB-401 Failed to Strike Primary Endpoint, Lowers PT to $3 from $73	21-09-03	MT
FORTE BIOSCIENCES : Truist Securities Downgrades Forte Biosciences to Hold from Buy	21-09-03	MT
FORTE BIOSCIENCES : B. Riley Starts Forte Biosciences at Buy with $73 PT, Says FB-401 Could Fill Gap for Steroid-Free Treatment for Atopic Dermatitis	21-05-14	MT
FORTE BIOSCIENCES : Citigroup Starts Forte Biosciences at Buy With $75 Price Target	21-03-26	MT
FORTE BIOSCIENCES : Chardan Capital Adjusts Price Target on Forte Biosciences to $105 From $115, Maintains Buy Rating	21-03-17	MT
FORTE BIOSCIENCES : Chardan Adjusts Forte Biosciences' Price Target to $115 From $110, Keeps at Buy	20-11-11	MT
Forte Biosciences : Shares Higher After Truist Initiates Coverage	20-08-25	DJ

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.581 USD

Average target price

3.375 USD

Spread / Average Target

+480.90%

High Price Target

4 USD

Spread / Highest target

+588.47%

Low Price Target

2.75 USD

Spread / Lowest Target

+373.32%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Forte Biosciences, Inc.

Brookline Capital Markets
Chardan
Brookline Capital Management
Ladenburg Thalmann
Truist Securities
B. Riley
Citigroup

Quarterly revenue - Rate of surprise

Company calendar